Dyne Therapeutics initiated with a Buy at Guggenheim

Guggenheim analyst Debjit Chattopadhyay initiated coverage of Dyne Therapeutics with a Buy rating and $33 price target. The firm believes the ACHIEVE trial, with data due in the second half of this year, may demonstrate superior splicing index versus competition at relatively low doses and that the DELIVER trial, whose readout is also expected in the second half may show treatment generating "clinically relevant dystrophin at commercially viable doses."